Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma · Immune Checkpoint Inhibitors · Anti-angiogenic Therapy · Second-line Treatment

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
Contact: Study coordinator (Ming Shi)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Lanzhou, China · Guangzhou, China

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bengbu, China · Hefei, China

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma · Conversion Therapy

Abroad (travel likely)RecruitingPHASE2

Tianjin, China